Medicover AB (publ)

Medicover AB (publ)

MCVEY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.52B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Medicover AB (publ)Medicover AB (publ)39.80.84%17%12.4

Earnings Call Q3 2026

November 4, 2026 - AI Summary

Strong ongoing performance (continuing operations): growth + margin momentum - Organic revenue growth 8%; total revenues +6% (continuing operations), with ~2% negative FX impact. - EBIT up 22% (another quarter of margin improvement; 7th consecutive quarter YoY margin expansion). - Adjusted EBITDA up 7.1% to EUR 70.9m; margin improved to 17.8% (from 17.6%). - Healthcare services: 8% organic growth with margin expansion; Sports & Wellness continuing strong trend; Diagnostics strengthening fee-for-service (supports pricing control).
Geography/country mix: Poland resilient; Germany and Romania under pressure - Poland: solid growth with strong membership build (4.1m members vs 3.6m prior, i.e., ~+14% YoY indicated). - Germany & Diagnostics: softness attributed to temporary vacation/staffing patterns; expected to normalize as longer-term treatment demand continues. - Romania: membership and hospitals issues persist—management attributes to pricing/account management changes, plus macroeconomic demand softness; actions underway, but visibility depends on execution and pipeline conversion.
Key headwinds acknowledged (including signaling for near-term wash-through effects) - Management is signaling near-term pressure from public reimbursement changes (notably Germany genetics reform), plus ongoing effects from: - Location/property repurposing (118 units closed over last ~12 months; revenue takes time to build in newly opened/repurposed units), - B2B cycle timing (member/funded/payer impacts can take months to reset—not overnight). - For Germany genetics, management said the impact is range-like/uncertain but expects to feel it and manage it over the next four quarters (wash-through strategy similar to prior German reform). - Diagnostics Q3: organic growth 8.5% (about 50/50 price and volume), but EBITDA margin flat at 14.3%, with softness driven by Germany and Genetics offset by Poland/Romania/SSE.

Exclusive for Stockcircle Pro members

Sign upSign Up
$15.65

Current Fair Value

5.4% downside

Overvalued by 5.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.52 Billion
Enterprise Value$3.72 Billion
Annual dividend$0.23
Dividend yield0.84%
Earnings per Share$0.51
Beta1.59
Outstanding Shares151,974,274

Return

Return on Equity16.88%ROE
Return on Assets3.74%
Return on Invested Capital13.26%

Valuation & Multiples

P/E Ratio39.84P/E Ratio
PEG131.4PEG
Price to Sales1.03Price to Sales
Price to Book Ratio5.52Price to Book Ratio
Enterprise Value to Revenue1.52
Enterprise Value to EBIT20.82
Enterprise Value to Net Income40
Total Debt to Enterprise0.35
Debt to Equity2.39Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Medicover AB (publ)

49,000 employees
CEO: John Paul Stubbington

Medicover AB (publ) delivers healthcare and diagnostic solutions across multiple countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company operates through...